AbbVie said net revenues for Q3 were $15.776 billion, an increase of 9.1% on a reported basis or 8.4% on an operational basis. Global net revenues from the immunology portfolio were $7.885 billion, an increase of 11.9% on a reported basis, with Skyrizi at $4.708 billion, Rinvoq at $2.184 billion and Humira at $993 million.

1. 01

   AbbVie said net revenues for Q3 were $15.776 billion, an increase of 9.1% on a reported basis or 8.4% on an operational basis. Global net revenues from the immunology portfolio were $7.885 billion, an increase of 11.9% on a reported basis, with Skyrizi at $4.708 billion, Rinvoq at $2.184 billion and Humira at $993 million.

2. 02

   The company said diluted earnings per share on a GAAP basis for Q3 were $0.10, a decrease of 88.6%, and adjusted diluted EPS were $1.86, a decrease of 38.0%. These results included an unfavorable impact of $1.50 per share related to acquired IPR&D and milestones expense.

3. 03

   AbbVie said operating margin on a GAAP basis for Q3 was 12.1% and adjusted operating margin was 30.9%. Acquired IPR&D and milestones expense was 17.0% of net revenues, and net interest expense was $667 million.

4. 04

   The company raised its adjusted diluted EPS guidance for full-year 2025 from $10.38 to $10.58 to $10.61 to $10.65. The board declared an increase in the quarterly cash dividend from $1.64 per share to $1.73 per share, an increase of approximately 5.5%, AbbVie said.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.